Cargando...
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
The past decade has witnessed major advances in our understanding of molecular biology, which led to breakthrough novel therapies, importantly including the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax. Notably, venetoclax-based combinations have improved outcomes, including both remission rates a...
Guardado en:
| Publicado en: | Front Oncol |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7675064/ https://ncbi.nlm.nih.gov/pubmed/33251134 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.562558 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|